AstraZeneca: positive phase III results for anifrolumab
(CercleFinance.com) - AstraZeneca today presented detailed results from a Phase III trial for a potential new treatment of severe systemic lupus erythematosus, which demonstrated superiority versus placebo.
On the primary endpoint, the drugmaker's anifrolumab achieved a statistically significant and clinically meaningful reduction in disease activity after one year, with 47.8% of patients responding compared with just 31.5% of patients on placebo.
The trial also showed statistically significant differences in multiple secondary endpoints, with 49% of patients experiencing improved skin manifestations at week 12, compared with just 25% for patients receiving placebo.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
On the primary endpoint, the drugmaker's anifrolumab achieved a statistically significant and clinically meaningful reduction in disease activity after one year, with 47.8% of patients responding compared with just 31.5% of patients on placebo.
The trial also showed statistically significant differences in multiple secondary endpoints, with 49% of patients experiencing improved skin manifestations at week 12, compared with just 25% for patients receiving placebo.
Copyright (c) 2019 CercleFinance.com. All rights reserved.